| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/21/2010 | EP2177620A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 04/21/2010 | EP2177619A1 HSV strains for the oncolytic treatment of cancer |
| 04/21/2010 | EP2177552A1 Bioabsorbable surgical composition |
| 04/21/2010 | EP2177527A1 2'-fluoro-4'-substituted nucleosides, the preparation and use |
| 04/21/2010 | EP2177526A1 10a-azalide compound crosslinked at position-10a and position-12 |
| 04/21/2010 | EP2177525A1 Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound |
| 04/21/2010 | EP2177523A1 Novel macrocyclic inhibitors of hepatitis c virus replication |
| 04/21/2010 | EP2177522A1 Novel carbapenem derivatives |
| 04/21/2010 | EP2177521A1 New 2-Amidothiadiazole Derivatives |
| 04/21/2010 | EP2177518A1 Organic compounds |
| 04/21/2010 | EP2177517A1 Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels |
| 04/21/2010 | EP2177513A1 Phenylacetic acid compound |
| 04/21/2010 | EP2177511A2 Process for preparing 3,6-disubstituted azabicyclo derivatives |
| 04/21/2010 | EP2177510A1 Allosteric protein kinase modulators |
| 04/21/2010 | EP2177505A1 Bicyclic acylguanidine derivative |
| 04/21/2010 | EP2177503A1 Modulators of cannabinoid receptors |
| 04/21/2010 | EP2177502A1 Compounds and their use |
| 04/21/2010 | EP2177226A1 Hydroxamate compositions |
| 04/21/2010 | EP2177225A1 Peritoneal dialysate |
| 04/21/2010 | EP2177224A2 Agents for preventing and treating disorders involving modulation of the RyR receptors |
| 04/21/2010 | EP2177223A2 Homoharringonine alone or combined with other agents for use in treating chronic myelogenous leukemia resistant or intolerant to sti571 |
| 04/21/2010 | EP2177222A1 Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| 04/21/2010 | EP2177221A1 Process for the preparation of substantially optically pure Repaglinide and precursors thereof |
| 04/21/2010 | EP2177220A1 Gel containing pirfenidone |
| 04/21/2010 | EP2177219A1 Preventive agent or therapeutic agent for disease caused by abnormal bone metabolism |
| 04/21/2010 | EP2177218A1 Regenerative therapy |
| 04/21/2010 | EP2177217A1 Composition comprising rotigotine, its use and transdermal patch comprising the composition |
| 04/21/2010 | EP2177216A1 Use of dianhydrohexite mononitrate derivatives as healing agents |
| 04/21/2010 | EP2177215A1 Co-crystals of tramadol and NSAIDs |
| 04/21/2010 | EP2177214A1 Solid Oral Dosage Forms and Uses |
| 04/21/2010 | EP2177213A1 Nicotine-containing granulate |
| 04/21/2010 | EP2177212A1 Methods of using lamellar bodies for therapeutic purposes |
| 04/21/2010 | EP2177210A1 Method of producing microparticles to be ingested into the body, microparticles to be ingested into the body and dispersion and medicinal composition containing the same |
| 04/21/2010 | EP2177209A1 Intravenous solutions and uses |
| 04/21/2010 | EP2177208A1 Pharmaceutical topical compositions |
| 04/21/2010 | EP2176411A2 Nanoparticle-mediated treatment for inflammatory diseases |
| 04/21/2010 | EP2176406A1 Compositions and methods of treating cancer |
| 04/21/2010 | EP2176299A1 An exopolysaccharide |
| 04/21/2010 | EP2176282A2 8-beta-substituted estratrienes as selectively active estrogens |
| 04/21/2010 | EP2176278A2 2',3'-di-o-acyl-5-fluoronucleosides |
| 04/21/2010 | EP2176276A2 Derivatives of nystatin and their use as antifungal agents |
| 04/21/2010 | EP2176275A1 Adefovir dipivoxil crystalline monohydrate form |
| 04/21/2010 | EP2176265A1 Imidazo [1, 2-c]pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists |
| 04/21/2010 | EP2176264A1 Imidazo-, pyrazolopyrazines and imidazotriazines and their use |
| 04/21/2010 | EP2176263A2 Fused quinoline derivatives useful as gaba modulators |
| 04/21/2010 | EP2176262A1 Tricyclic compounds as antibacterials |
| 04/21/2010 | EP2176260A1 Pyrazolo[1,5-a]pyridines and their use in cancer therapy |
| 04/21/2010 | EP2176259A1 Fused imidazoles for cancer treatment |
| 04/21/2010 | EP2176258A1 Piperidine derivatives useful as orexin receptor antagonists |
| 04/21/2010 | EP2176256A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 04/21/2010 | EP2176255A1 Andrographolide derivatives and use thereof in manufacture of medicaments |
| 04/21/2010 | EP2176254A1 Dna pk inhibitors |
| 04/21/2010 | EP2176253A2 A process for the preparation or purification of olmesartan medoxomil |
| 04/21/2010 | EP2176252A1 2, 3-dihydrobenzo[1, 4]dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases |
| 04/21/2010 | EP2176251A2 5-pyridinone substituted indazoles |
| 04/21/2010 | EP2176250A1 Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators |
| 04/21/2010 | EP2176249A2 New chemical compounds |
| 04/21/2010 | EP2176248A1 New antimicrobial compounds, their synthesis and their use for treatment of mammalian infections |
| 04/21/2010 | EP2176247A2 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| 04/21/2010 | EP2176241A2 A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
| 04/21/2010 | EP2176240A1 Amine salts of a crth2 antagonist |
| 04/21/2010 | EP2176238A1 Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| 04/21/2010 | EP2176237A1 Phthalazinone derivatives as inhibitors of parp-1 |
| 04/21/2010 | EP2176236A1 6-thioxo-pyridazine derivatives |
| 04/21/2010 | EP2176234A2 Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid |
| 04/21/2010 | EP2176233A1 Gamma secretase modulators |
| 04/21/2010 | EP2176231A1 Substituted indazole derivatives active as kinase inhibitors |
| 04/21/2010 | EP2176230A2 Treatment of duchenne muscular dystrophy |
| 04/21/2010 | EP2176223A1 Malonamide derivatives with antithrombotic activity |
| 04/21/2010 | EP2176221A1 Indole indane amide compounds useful as cb2 agonists and method |
| 04/21/2010 | EP2176220A2 Pyrrolidin-2-one derivatives as androgen receptor modulator |
| 04/21/2010 | EP2176219A1 Novel compounds as cannabinoid receptor ligands |
| 04/21/2010 | EP2176218A2 Stereoisomers of tricyclodecan-9-yl-xanthogenate |
| 04/21/2010 | EP2176217A1 Amino acid derivatives |
| 04/21/2010 | EP2176211A1 Organic compounds |
| 04/21/2010 | EP2176208A1 Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
| 04/21/2010 | EP2175886A1 Combination methods and compositions for treatment of neuropathic pain |
| 04/21/2010 | EP2175879A1 Treatment of prion protein related diseases |
| 04/21/2010 | EP2175866A1 Novel one step process for preparing cross-linked poly(allylamine) polymers |
| 04/21/2010 | EP2175865A2 Controlled release interferon drug products and treatment of hcv infection using same |
| 04/21/2010 | EP2175864A2 Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages |
| 04/21/2010 | EP2175863A2 Substituted nucleoside derivatives with antiviral and antimicrobial properties |
| 04/21/2010 | EP2175862A1 Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
| 04/21/2010 | EP2175860A2 Nr4a agonists (6-mercaptopurine) for inhibition of non-ocular scarring |
| 04/21/2010 | EP2175859A1 Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
| 04/21/2010 | EP2175858A1 Pharmaceutical compositions and methods of treating dry eye disorders |
| 04/21/2010 | EP2175857A2 Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| 04/21/2010 | EP2175856A2 Novel process for preparing highly pure levocetirizine and salts thereof |
| 04/21/2010 | EP2175855A1 Stable pharmaceutical composition of a water-soluble vinorelbine salt |
| 04/21/2010 | EP2175853A1 Methods of treating metabolic syndrome using dopamine receptor agonists |
| 04/21/2010 | EP2175852A1 N-(2-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases |
| 04/21/2010 | EP2175851A1 Biofilm treatment |
| 04/21/2010 | EP2175850A1 Methods for treating anxiety |
| 04/21/2010 | EP2175848A1 Therapeutic uses of cannabigerol |
| 04/21/2010 | EP2175847A1 Cyclodextrin-based nanosponges as a vehicle for antitumoral drugs |
| 04/21/2010 | EP2175844A1 Substituted fluoroethyl ureas as alpha 2 adrenergic agents |
| 04/21/2010 | EP2175843A2 Extended release compositions comprising tolterodine |
| 04/21/2010 | EP2175840A2 Pharmaceutical compositions comprising ropinirole |
| 04/21/2010 | EP2175839A1 Controlled release pharmaceutical composition of tolperison hydrochloride |
| 04/21/2010 | EP2175838A2 An inhalable medicament |